Abstract:Granulocyte‐colony‐stimulating‐factor (G‐CSF) activates signal transducer and activator of transcription 3 (STAT3) by the colony‐stimulating‐factor 3 receptor (CSF3R), then phosphorylated STAT3 enters into nucleus and upregulates suppressor of cytokine signaling 1 (SOCS1) by reorganizing chromatin structure around the SOCS1 locus. Activating SOCS1 prevents T‐cell activationand graft‐versus‐host disease by inhibiting CSF3R, STAT3, and NOD‐, LRR‐ and pyrin domain‐containing protein 3 (NLRP3) inflammasome activation. Graft‐versus‐host disease (GVHD) is a major life‐threatening complication of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Inflammatory signaling pathways promote T‐cell activation and are involved in the pathogenesis of GVHD. Suppressor of cytokine signaling 1 (SOCS1) is a critical negative regulator for several inflammatory cytokines. However, its regulatory role in T‐cell activation and GVHD has not been elucidated. Multiomics analysis of the transcriptome and chromatin structure of granulocyte‐colony‐stimulating‐factor (G‐CSF)‐administered hyporesponsive T cells from healthy donors reveal that G‐CSF upregulates SOCS1 by reorganizing the chromatin structure around the SOCS1 locus. Parallel in vitro and in vivo analyses demonstrate that SOCS1 is critical for restraining T cell activation. Loss of Socs1 in T cells exacerbates GVHD pathogenesis and diminishes the protective role of G‐CSF in GVHD mouse models. Further analysis shows that SOCS1 inhibits T cell activation not only by inhibiting the colony‐stimulating‐factor 3 receptor (CSF3R)/Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway, but also by restraining activation of the inflammasome signaling pathway. Moreover, high expression of SOCS1 in T cells from patients correlates with low acute GVHD occurrence after HSCT. Overall, these findings identify that SOCS1 is critical for inhibiting T cell activation and represents a potential target for the attenuation of GVHD.

[SOCS3: a Potential Therapeutic Target for Many Human Diseases].

Relationship Between Suppressor of Cytokine Signaling -3 and Cell Migration and Invasion

SOCS Signaling in Autoimmune Diseases: Molecular Mechanisms and Therapeutic Implications.

SOCS Proteins in Immunity, Inflammatory Diseases, and Immune-Related Cancer

SOCS modulates JAK-STAT pathway as a novel target to mediate the occurrence of neuroinflammation: Molecular details and treatment options

The Role of Suppressor of Cytokine Signaling 3 in Inflammatory Bowel Disease and Its Associated Colorectal Cancer

The Neglected Suppressor of Cytokine Signalling (SOCS): SOCS4-7

Regulation of Insulin and Leptin Signaling by Muscle Suppressor of Cytokine Signaling 3 (SOCS3)

The Role and Gene Expression Profile of SOCS3 in Colorectal Carcinoma.

Suppressor of Cytokine Signaling 1 Haploinsufficiency

Suppressor of Cytokine Signaling-1 and Lung Diseases

Characterization of the Roles of Suppressor of Cytokine Signaling‐3 in Prostate Cancer Development and Progression

The Role of Microtubule-Associated Protein 1s in Socs3 Regulation of Il-6 Signaling

Suppressor of cytokine signaling 6 in cancer development and therapy: Deciphering its emerging and suppressive roles

SOCS Proteins Participate in the Regulation of Innate Immune Response Caused by Viruses

SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation

SOCS3 Drives Proteasomal Degradation of TBK1 and Negatively Regulates Antiviral Innate Immunity.

Multiomics Analysis Identifies SOCS1 as Restraining T Cell Activation and Preventing Graft‐Versus‐Host Disease

Aberrant expression of suppressor of cytokine signaling (SOCS) molecules contributes to the development of allergic diseases

Unveiling the pathological functions of SOCS in colorectal cancer: Current concepts and future perspectives

SOCS3 as a potential driver of lung metastasis in colon cancer patients